KEGG   DRUG: Glecaprevir and pibrentasvir
Entry
D11014            Mixture   Drug                                   
Name
Glecaprevir and pibrentasvir;
Mavyret (TN)
Product
MAVYRET (AbbVie)
Component
(Glecaprevir [DR:D10814] | Glecaprevir hydrate [DR:D10815]), Pibrentasvir [DR:D10816]
Class
Antiviral
 DG03198  Anti-HCV agent
Transporter substrate
 DG01665  ABCB1 substrate
 DG01913  ABCG2 substrate
 DG02856  SLCO1B1 substrate
 DG02932  SLCO1B3 substrate
Transporter inhibitor
 DG01622  ABCB1 inhibitor
 DG02862  ABCG2 inhibitor
 DG02865  SLCO1B1 inhibitor
 DG02907  SLCO1B3 inhibitor
Remark
Therapeutic category: 6250
ATC code: J05AP57
Product: D11014<JP/US>
Efficacy
Antiviral
  Disease
Chronic hepatitis C virus infection [DS:H00413]
Comment
Glecaprevir is an inhibitor and a substrate of P-gp, BCRP, OATP1B1/1B3.
Pibrentasvir is a substrate of P-gp; it is also an inhibitor of P-gp, BCRP and OATP1B1.
Target
HCV NS3/4A protease [KO:K22273 K22274]
HCV NS5A [KO:K22275]
Metabolism
Transporter: ABCB1 [HSA:5243], ABCG2 [HSA:9429], SLCO1B1 [HSA:10599], SLCO1B3 [HSA:28234]
Interaction
Transporter inhibition: ABCB1 [HSA:5243], ABCG2 [HSA:9429], SLCO1B1 [HSA:10599], SLCO1B3 [HSA:28234]
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 J ANTIINFECTIVES FOR SYSTEMIC USE
  J05 ANTIVIRALS FOR SYSTEMIC USE
   J05A DIRECT ACTING ANTIVIRALS
    J05AP Antivirals for treatment of HCV infections
     J05AP57 Glecaprevir and pibrentasvir
      D11014  Glecaprevir and pibrentasvir <JP/US>
USP drug classification [BR:br08302]
 Antivirals
  Anti-hepatitis C (HCV) Agents
   Glecaprevir/ Pibrentasvir
    D11014  Glecaprevir and pibrentasvir
Therapeutic category of drugs in Japan [BR:br08301]
 6  Agents against pathologic organisms and parasites
  62  Chemotherapeutics
   625  Antivirals
    6250  Antivirals
     D11014  Glecaprevir and pibrentasvir
Drug groups [BR:br08330]
 Antiviral
  DG03198  Anti-HCV agent
   D11014  Glecaprevir and pibrentasvir
 Transporter substrate
  DG01665  ABCB1 substrate
   D11014  Glecaprevir and pibrentasvir
  DG01913  ABCG2 substrate
   D11014  Glecaprevir and pibrentasvir
  DG02856  SLCO1B1 substrate
   D11014  Glecaprevir and pibrentasvir
  DG02932  SLCO1B3 substrate
   D11014  Glecaprevir and pibrentasvir
 Transporter inhibitor
  DG01622  ABCB1 inhibitor
   D11014  Glecaprevir and pibrentasvir
  DG02862  ABCG2 inhibitor
   D11014  Glecaprevir and pibrentasvir
  DG02865  SLCO1B1 inhibitor
   D11014  Glecaprevir and pibrentasvir
  DG02907  SLCO1B3 inhibitor
   D11014  Glecaprevir and pibrentasvir
Drug classes [BR:br08332]
 Antiviral
  DG03198  Anti-HCV agent
   D11014  Glecaprevir and pibrentasvir
Antimicrobials [BR:br08307]
 Antivirals
  Polyprotein cleavage inhibitor
   HCV NS3/4A inhibitor
    D11014  Glecaprevir and pibrentasvir <JP/US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D11014
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D11014
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D11014
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D11014
Drug metabolizing enzymes and transporters [br08309.html]
 Drug transporters
  D11014
Other DBs
PubChem: 348350486
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system